1
|
Sempos CT, Williams EL, Carter GD, Jones J, Camara JE, Burdette CQ, Hahm G, Nalin F, Duewer DL, Kuszak AJ, Merkel J, Hoofnagle AN, Lukas P, Cavalier É, Durazo-Arvizu RA, Crump PM, Popp C, Beckert C, Schultess J, Van Slooten G, Tourneur C, Pease C, Kaul R, Villarreal A, Ivison F, Fischer R, van den Ouweland JMW, Ho CS, Law EWK, Simard JN, Gonthier R, Holmquist B, Batista MC, Meadows S, Cox L, Jansen E, Khan DA, Robyak K, Creer MH, Kilbane M, Twomey PJ, Freeman J, Parker N, Yuan J, Fitzgerald R, Mushtaq S, Clarke MW, Breen N, Simpson C, Wise SA. Assessment of serum total 25-hydroxyvitamin D assays for Vitamin D External Quality Assessment Scheme (DEQAS) materials distributed at ambient and frozen conditions. Anal Bioanal Chem 2021; 414:1015-1028. [PMID: 34750644 DOI: 10.1007/s00216-021-03742-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 10/12/2021] [Accepted: 10/18/2021] [Indexed: 10/19/2022]
Abstract
The Vitamin D External Quality Assessment Scheme (DEQAS) distributes human serum samples four times per year to over 1000 participants worldwide for the determination of total serum 25-hydroxyvitamin D [25(OH)D)]. These samples are stored at -40 °C prior to distribution and the participants are instructed to store the samples frozen at -20 °C or lower after receipt; however, the samples are shipped to participants at ambient conditions (i.e., no temperature control). To address the question of whether shipment at ambient conditions is sufficient for reliable performance of various 25(OH)D assays, the equivalence of DEQAS human serum samples shipped under frozen and ambient conditions was assessed. As part of a Vitamin D Standardization Program (VDSP) commutability study, two sets of the same nine DEQAS samples were shipped to participants at ambient temperature and frozen on dry ice. Twenty-eight laboratories participated in this study and provided 34 sets of results for the measurement of 25(OH)D using 20 ligand binding assays and 14 liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods. Equivalence of the assay response for the frozen versus ambient DEQAS samples for each assay was evaluated using multi-level modeling, paired t-tests including a false discovery rate (FDR) approach, and ordinary least squares linear regression analysis of frozen versus ambient results. Using the paired t-test and confirmed by FDR testing, differences in the results for the ambient and frozen samples were found to be statistically significant at p < 0.05 for four assays (DiaSorin, DIAsource, Siemens, and SNIBE prototype). For all 14 LC-MS/MS assays, the differences in the results for the ambient- and frozen-shipped samples were not found to be significant at p < 0.05 indicating that these analytes were stable during shipment at ambient conditions. Even though assay results have been shown to vary considerably among different 25(OH)D assays in other studies, the results of this study also indicate that sample handling/transport conditions may influence 25(OH)D assay response for several assays.
Collapse
Affiliation(s)
- Christopher T Sempos
- Office of Dietary Supplements (ODS), National Institutes of Health (NIH), Bethesda, MD, 20892, USA.,Vitamin D Standardization Program LLC, Havre de Grace, MD, 21078, USA
| | | | | | - Julia Jones
- Imperial Healthcare NHS Trust, London, W6 8RF, UK
| | - Johanna E Camara
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Carolyn Q Burdette
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Grace Hahm
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Federica Nalin
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - David L Duewer
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Adam J Kuszak
- Office of Dietary Supplements (ODS), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Joyce Merkel
- Office of Dietary Supplements (ODS), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Andrew N Hoofnagle
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, 98185, USA
| | - Pierre Lukas
- Clinical Chemistry, University of Liège, CHU de Liège, 4000, Liège, Belgium
| | - Étienne Cavalier
- Clinical Chemistry, University of Liège, CHU de Liège, 4000, Liège, Belgium
| | - Ramón A Durazo-Arvizu
- Biostatistics Core, The Sabin Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90027, USA
| | - Peter M Crump
- Computing and Biometry, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Christian Popp
- Abbott Laboratories, ADD Wiesbaden Abbott GmbH, 65205, Wiesbaden, Germany
| | - Christian Beckert
- Abbott Laboratories, ADD Wiesbaden Abbott GmbH, 65205, Wiesbaden, Germany
| | - Jan Schultess
- Abbott Laboratories, ADD Wiesbaden Abbott GmbH, 65205, Wiesbaden, Germany
| | | | | | | | - Ravi Kaul
- Bio-Rad Laboratories, Clinical Diagnostics, Hercules, CA, 94547, USA
| | | | - Fiona Ivison
- Central Manchester Foundation Trust, Manchester, M13 9WL, UK
| | - Ralf Fischer
- Chromsystems Instruments & Chemicals GmbH, 82166, Gräfelfing, Germany
| | | | - Chung S Ho
- Biochemical Mass Spectrometry Unit, Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, 999077
| | - Emmett W K Law
- Biochemical Mass Spectrometry Unit, Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, 999077
| | | | | | - Brett Holmquist
- Endocrine Sciences, LabCorp Specialty Testing Group, Agoura Hills, CA, 91301, USA
| | | | - Sarah Meadows
- Medical Research Council (MRC) Elsie Widdowson Laboratory (Closed Dec. 2018), Cambridge, CB2 0SL, UK.,NIHR BRC Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, CB2 0SL, UK
| | - Lorna Cox
- Medical Research Council (MRC) Elsie Widdowson Laboratory (Closed Dec. 2018), Cambridge, CB2 0SL, UK.,NIHR BRC Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, CB2 0SL, UK
| | - Eugene Jansen
- National Institute of Public Health and the Environment (RIVM), 3720 BA, Bilthoven, The Netherlands
| | - Dilshad Ahmed Khan
- National University of Medical Sciences (NUMS), Rawalpindi, 46000, Punjab, Pakistan
| | - Kimberly Robyak
- College of Medicine, Penn State University, Hershey, PA, 17033, USA
| | - Michael H Creer
- College of Medicine, Penn State University, Hershey, PA, 17033, USA
| | - Mark Kilbane
- Clinical Chemistry, St. Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland
| | - Patrick J Twomey
- Clinical Chemistry, St. Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland
| | | | - Neil Parker
- Siemens-Healthineers, Tarrytown, NY, 10591, USA
| | - Jinyun Yuan
- SNIBE, Shenzhen, 518122, People's Republic of China
| | - Robert Fitzgerald
- Health Clinical Laboratories, University of California at San Diego, La Jolla, CA, 92093, USA
| | | | - Michael W Clarke
- Metabolomics Australia, Centre for Microscopy, Characterisation and Analysis, The University of Western Australia, Perth, WA, 6009, Australia
| | - Norma Breen
- Waters Technologies Ireland Ltd., Wexford, Y35 D431, Ireland
| | | | - Stephen A Wise
- Office of Dietary Supplements (ODS), National Institutes of Health (NIH), Bethesda, MD, 20892, USA. .,Scientist Emeritus, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA.
| |
Collapse
|
2
|
Camara JE, Wise SA, Hoofnagle AN, Williams EL, Carter GD, Jones J, Burdette CQ, Hahm G, Nalin F, Kuszak AJ, Merkel J, Durazo-Arvizu RA, Lukas P, Cavalier É, Popp C, Beckert C, Schultess J, Van Slooten G, Tourneur C, Pease C, Kaul R, Villarreal A, Ivison F, Fischer R, van den Ouweland JMW, Ho CS, Law EWK, Simard JN, Gonthier R, Holmquist B, Batista MC, Pham H, Bennett A, Meadows S, Cox L, Jansen E, Khan DA, Robyak K, Creer MH, Kilbane M, Twomey PJ, Freeman J, Parker N, Yuan J, Fitzgerald R, Mushtaq S, Clarke MW, Breen N, Simpson C, Sempos CT. Assessment of serum total 25-hydroxyvitamin D assay commutability of Standard Reference Materials and College of American Pathologists Accuracy-Based Vitamin D (ABVD) Scheme and Vitamin D External Quality Assessment Scheme (DEQAS) materials: Vitamin D Standardization Program (VDSP) Commutability Study 2. Anal Bioanal Chem 2021; 413:5067-5084. [PMID: 34184102 PMCID: PMC8431775 DOI: 10.1007/s00216-021-03470-w] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 05/29/2021] [Accepted: 06/09/2021] [Indexed: 10/21/2022]
Abstract
An interlaboratory study was conducted through the Vitamin D Standardization Program (VDSP) to assess commutability of Standard Reference Materials® (SRMs) and proficiency testing/external quality assessment (PT/EQA) samples for determination of serum total 25-hydroxyvitamin D [25(OH)D] using ligand binding assays and liquid chromatography-tandem mass spectrometry (LC-MS/MS). A set of 50 single-donor serum samples were assigned target values for 25-hydroxyvitamin D2 [25(OH)D2] and 25-hydroxyvitamin D3 [25(OH)D3] using reference measurement procedures (RMPs). SRM and PT/EQA samples evaluated included SRM 972a (four levels), SRM 2973, six College of American Pathologists (CAP) Accuracy-Based Vitamin D (ABVD) samples, and nine Vitamin D External Quality Assessment Scheme (DEQAS) samples. Results were received from 28 different laboratories using 20 ligand binding assays and 14 LC-MS/MS methods. Using the test assay results for total serum 25(OH)D (i.e., the sum of 25(OH)D2 and 25(OH)D3) determined for the single-donor samples and the RMP target values, the linear regression and 95% prediction intervals (PIs) were calculated. Using a subset of 42 samples that had concentrations of 25(OH)D2 below 30 nmol/L, one or more of the SRM and PT/EQA samples with high concentrations of 25(OH)D2 were deemed non-commutable using 5 of 11 unique ligand binding assays. SRM 972a (level 4), which has high exogenous concentration of 3-epi-25(OH)D3, was deemed non-commutable for 50% of the LC-MS/MS assays.
Collapse
Affiliation(s)
- Johanna E Camara
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Stephen A Wise
- Scientist Emeritus, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA.
- Office of Dietary Supplements (ODS), National Institutes of Health (NIH), Bethesda, MD, 20892, USA.
| | - Andrew N Hoofnagle
- Department of Laboratory Medicine, University of Washington, Seattle, WA, 98185, USA
| | | | | | - Julia Jones
- Imperial Healthcare NHS Trust, London, W6 8RF, UK
| | - Carolyn Q Burdette
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Grace Hahm
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Federica Nalin
- Chemical Sciences Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Adam J Kuszak
- Office of Dietary Supplements (ODS), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Joyce Merkel
- Office of Dietary Supplements (ODS), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Ramón A Durazo-Arvizu
- Biostatistics Core, The Sabin Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90027, USA
| | - Pierre Lukas
- Clinical Chemistry, University of Liège, CHU de Liège, 4000, Liège, Belgium
| | - Étienne Cavalier
- Clinical Chemistry, University of Liège, CHU de Liège, 4000, Liège, Belgium
| | - Christian Popp
- Abbott Laboratories, ADD Wiesbaden Abbott GmbH, 65205, Wiesbaden, Germany
| | - Christian Beckert
- Abbott Laboratories, ADD Wiesbaden Abbott GmbH, 65205, Wiesbaden, Germany
| | - Jan Schultess
- Abbott Laboratories, ADD Wiesbaden Abbott GmbH, 65205, Wiesbaden, Germany
| | | | | | | | - Ravi Kaul
- Clinical Diagnostics, Bio-Rad Laboratories, Clinical Diagnostics, Hercules, CA, 94547, USA
| | - Alfredo Villarreal
- Clinical Diagnostics, Bio-Rad Laboratories, Clinical Diagnostics, Hercules, CA, 94547, USA
| | - Fiona Ivison
- Central Manchester Foundation Trust, Manchester, M13 9WL, UK
| | - Ralf Fischer
- Chromsystems Instruments & Chemicals GmbH, 82166, Gräfelfing, Germany
| | | | - Chung S Ho
- Biomedical Mass Spectrometry Unit, Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, 999077, Hong Kong
| | - Emmett W K Law
- Biomedical Mass Spectrometry Unit, Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, 999077, Hong Kong
| | | | | | - Brett Holmquist
- LabCorp Specialty Testing Group, Endocrine Sciences, Agoura Hills, CA, 91301, USA
| | | | - Heather Pham
- Immunodiagnostic Systems (IDS), Boldon, NE35 9PD, UK
| | - Alex Bennett
- Immunodiagnostic Systems (IDS), Boldon, NE35 9PD, UK
| | - Sarah Meadows
- Medical Research Council (MRC) Elsie Widdowson Laboratory (closed Dec. 2018), Cambridge, CB2 0SL, UK
- NIHR BRC Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, CB2 0SL, UK
| | - Lorna Cox
- Medical Research Council (MRC) Elsie Widdowson Laboratory (closed Dec. 2018), Cambridge, CB2 0SL, UK
- NIHR BRC Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, CB2 0SL, UK
| | - Eugene Jansen
- National Institute of Public Health and the Environment (RIVM), 3720 BA, Bilthoven, The Netherlands
| | - Dilshad Ahmed Khan
- National University of Medical Sciences (NUMS), Rawalpindi, Punjab, 46000, Pakistan
| | - Kimberly Robyak
- College of Medicine, Penn State University, Hershey, PA, 17033, USA
| | - Michael H Creer
- College of Medicine, Penn State University, Hershey, PA, 17033, USA
| | - Mark Kilbane
- Clinical Chemistry, St. Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland
| | - Patrick J Twomey
- Clinical Chemistry, St. Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland
| | | | - Neil Parker
- Siemens-Healthineers, Tarrytown, NY, 10591, USA
| | - Jinyun Yuan
- SNIBE, Shenzhen, 518122, People's Republic of China
| | - Robert Fitzgerald
- University of California at San Diego, Health Clinical Laboratories, La Jolla, CA, 92093, USA
| | | | - Michael W Clarke
- Metabolomics Australia, Centre for Microscopy, Characterisation and Analysis, The University of Western Australia, Perth, WA, 6009, Australia
| | - Norma Breen
- Waters Technologies Ireland Ltd., Wexford, Y35 D431, Ireland
| | | | - Christopher T Sempos
- Office of Dietary Supplements (ODS), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
- Vitamin D Standardization Program LLC, Havre de Grace, MD, 21078, USA
| |
Collapse
|
3
|
Kuhns MC, Holzmayer V, McNamara AL, Sickinger E, Schultess J, Cloherty GA. Improved detection of early acute, late acute, and occult Hepatitis B infections by an increased sensitivity HBsAg assay. J Clin Virol 2019; 118:41-45. [PMID: 31442662 DOI: 10.1016/j.jcv.2019.08.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Revised: 06/07/2019] [Accepted: 08/01/2019] [Indexed: 02/06/2023]
Abstract
BACKGROUND Hepatitis B surface antigen (HBsAg) is the primary marker for diagnosis of acute and chronic hepatitis B. Although HBsAg assays have undergone continuous improvement, gaps remain in the detection of early and late acute infection and occult hepatitis B infection (OBI). OBJECTIVES The performance of a prototype, improved sensitivity HBsAg assay run on the ARCHITECT and Alinity instruments was evaluated for detection of early and late acute infection and OBI. STUDY DESIGN Seventy seven early acute samples [positive only for hepatitis B viral DNA (HBV DNA)], twelve seroconversion panels spanning late acute infection, and 101 occult samples (HBsAg negative, positive for HBV DNA and anti-HBc) were tested with the prototype assay and ARCHITECT HBsAg Qualitative II. HBsAg gene sequencing was performed to determine genotype and mutations in the immunodominant region. RESULTS Compared with ARCHITECT HBsAg Qualitative II, the prototype assay showed increased detection of NAT yield samples (28/77, 36.4%,), late acute samples (≥13 days longer detection of HBsAg for 6/12 panels), and OBI samples (11/101, 10.9%). HBsAg sequence data were obtained for 62 samples. Genotypes represented were A1, A2, B2, B4, C1, C2, C5, D3, E, and H. HBsAg escape mutations were found in 4.8% of NAT yield and 38.9% of OBI samples sequenced. Prototype assay values for 188 samples were equivalent on the ARCHITECT and Alinity instruments. CONCLUSIONS The new prototype HBsAg assay will be of diagnostic value in providing improved detection of early acute, late acute, and occult HBV infections.
Collapse
Affiliation(s)
- Mary C Kuhns
- Infectious Disease Research, Diagnostics Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA.
| | - Vera Holzmayer
- Infectious Disease Research, Diagnostics Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA.
| | - Anne L McNamara
- Infectious Disease Research, Diagnostics Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
| | - Eva Sickinger
- Research and Development, Diagnostics Division, Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden-Delkenheim, Germany.
| | - Jan Schultess
- Research and Development, Diagnostics Division, Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden-Delkenheim, Germany.
| | - Gavin A Cloherty
- Infectious Disease Research, Diagnostics Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA.
| |
Collapse
|
4
|
Sickinger E, Braun H, Schultess J, Oer M. Performance evaluation of a new next-generation high-sensitive architect HBsAg assay. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.1166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Schultess J, van Duren C, Martens M, Costa M, Llop T, Martí T, Eppinger M, Hausmann M, Krack W, Dhein J. Diagnostic performance of the ARCHITECT C-Peptide immunoassay. Clin Chem Lab Med 2009; 47:834-41. [DOI: 10.1515/cclm.2009.185] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
6
|
Sickinger E, Gay-Andrieu F, Jonas G, Schultess J, Stieler M, Smith D, Hausmann M, Stricker R, Stricker R, Dhein J, Braun HB. Performance characteristics of the new ARCHITECT Toxo IgG and Toxo IgG Avidity assays. Diagn Microbiol Infect Dis 2008; 62:235-44. [PMID: 18715735 DOI: 10.1016/j.diagmicrobio.2008.07.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2008] [Revised: 07/02/2008] [Accepted: 07/09/2008] [Indexed: 11/28/2022]
Abstract
The ARCHITECT Toxo IgG and IgG Avidity assays have been developed as a fully automated panel for immune status determination and acute infection exclusion. Resolved relative specificity and sensitivity of the ARCHITECT Toxo IgG assay were 99.6% (1359/1365) and 99.7% (1096/1099) as determined on pregnant females, blood donor, and diagnostic specimens. Seroconversion sensitivity of the ARCHITECT assay was comparable with the AxSYM Toxo IgG assay. The ARCHITECT Toxo IgG Avidity assay detected 100.0% (124/124) of acute phase specimens (<4 months after infection) as low avidity, whereas the Vidas Toxo IgG Avidity assay detected 98.9% (89/90) as low avidity. In summary, the ARCHITECT Toxo IgG assay, using recombinant antigens, showed excellent specificity and sensitivity for acute phase as well as past infection specimens. The ARCHITECT Toxoplasmosis panel can be reliably used to rule out acute Toxoplasma gondii infection in pregnant women.
Collapse
Affiliation(s)
- Eva Sickinger
- Abbott GmbH & Co. KG, Max-Planck-Ring 2, D-65205 Wiesbaden-Delkenheim, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Hoffmeister M, Riha P, Neumüller O, Danielewski O, Schultess J, Smolenski AP. Cyclic nucleotide-dependent protein kinases inhibit binding of 14-3-3 to the GTPase-activating protein Rap1GAP2 in platelets. J Biol Chem 2007; 283:2297-306. [PMID: 18039662 DOI: 10.1074/jbc.m706825200] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
GTPase-activating proteins are required to terminate signaling by Rap1, a small guanine nucleotide-binding protein that controls integrin activity and cell adhesion. Recently, we identified Rap1GAP2, a GTPase-activating protein of Rap1 in platelets. Here we show that 14-3-3 proteins interact with phosphorylated serine 9 at the N terminus of Rap1GAP2. Platelet activation by ADP and thrombin enhances serine 9 phosphorylation and increases 14-3-3 binding to endogenous Rap1GAP2. Conversely, inhibition of platelets by endothelium-derived factors nitric oxide and prostacyclin disrupts 14-3-3 binding. These effects are mediated by cGMP- and cAMP-dependent protein kinases that phosphorylate Rap1GAP2 at serine 7, adjacent to the 14-3-3 binding site. 14-3-3 binding does not change the GTPase-activating function of Rap1GAP2 in vitro. However, 14-3-3 binding attenuates Rap1GAP2 mediated inhibition of cell adhesion. Our findings define a novel crossover point of activatory and inhibitory signaling pathways in platelets.
Collapse
Affiliation(s)
- Meike Hoffmeister
- Institute of Biochemistry II, University of Frankfurt Medical School, 60590 Frankfurt, Germany
| | | | | | | | | | | |
Collapse
|
8
|
Smolenski A, Hoffmeister M, Riha P, Neumüller O, Danielewski O, Schultess J. cGMP-dependent protein kinase regulates Rap1 signaling in platelets. BMC Pharmacol 2007. [DOI: 10.1186/1471-2210-7-s1-p56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
9
|
Schultess J, Sickinger E, Dhein J, Hausmann M, Smith D, Frias E, Palafox M, Prostko J, Pucci D, Stricker R, Stricker R, Thulliez P, Braun H. P552 Improved performance of the automated toxoplasmosis IgG, IgM & IgG avidity assays on the Abbott ARCHITECT Instrument. Int J Antimicrob Agents 2007. [DOI: 10.1016/s0924-8579(07)70395-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Schaffeld M, Schultess J. Genes coding for intermediate filament proteins closely related to the hagfish "thread keratins (TK)" alpha and gamma also exist in lamprey, teleosts and amphibians. Exp Cell Res 2006; 312:1447-62. [PMID: 16494865 DOI: 10.1016/j.yexcr.2006.01.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2005] [Revised: 01/09/2006] [Accepted: 01/10/2006] [Indexed: 01/16/2023]
Abstract
The "thread keratins (TK)" alpha and gamma so far have been considered highly specialized intermediate filament (IF) proteins restricted to hagfish. From lamprey, we now have sequenced five novel IF proteins closely related to TKalpha and TKgamma, respectively. Moreover, we have detected corresponding sequences in EST and genomic databases of teleosts and amphibians. The structure of the TKalpha genes and the positions of their deduced amino acid sequences in a phylogenetic tree clearly support their classification as type II keratins. The genes encoding TKgamma show a structure typical for type III IF proteins, whereas their positions in phylogenetic trees favor a close relationship to the type I keratins. Considering that most keratin-like sequences detected in the lancelet also exhibit a gene structure typical for type III IF proteins, it seems likely that the keratin gene(s) originated from an ancient type III IF protein gene. According to EST analyses, the expression of the thread keratins in teleost fish and amphibians may be particularly restricted to larval stages, which, in conjunction with the observed absence of TKalpha and TKgamma genes in any of the available Amniota databases, indicates a thread keratin function closely related to larval development in an aquatic environment.
Collapse
Affiliation(s)
- Michael Schaffeld
- Institute of Zoology, Johannes-von-Müller-Weg 6, Johannes Gutenberg University, D-55099 Mainz, Germany.
| | | |
Collapse
|
11
|
Danielewski O, Schultess J, Smolenski A. The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost 2005; 93:319-25. [PMID: 15711749 DOI: 10.1160/th04-09-0582] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The NO/cGMP signalling pathway strongly inhibits agonist-induced platelet aggregation. However, the molecular mechanisms involved are not completely defined. We have studied NO/cGMP effects on the activity of Rap 1, an abundant guanine-nucleotidebinding protein in platelets. Rap 1-GTP levels were reduced by NO-donors and activators of NO-sensitive soluble guanylyl cyclase. Four lines of evidence suggest that NO/cGMP effects are mediated by cGMP-dependent protein kinase (cGKI): (i) Rap 1 inhibition correlated with cGKI activity as measured by the phosphorylation state of VASP, an established substrate of cGKI, (ii) 8-pCPT-cGMP, a membrane permeable cGMP-analog and activator of cGKI, completely blocked Rap1 activation, (iii) Rp-8pCPT-cGMPS, a cGKI inhibitor, reversed NO effects and (iv) expression of cGKI in cGKI-deficient megakaryocytes inhibited Rap1 activation. NO/cGMP/cGKI effects were independent of the type of stimulus used for Rap1 activation. Thrombin-,ADP- and collagen-induced formation of Rap 1-GTP in platelets as well as turbulence-induced Rap 1 activation in megakaryocytes were inhibited. Furthermore, cGKI inhibited ADP-induced Rap 1 activation induced by the Galpha(i)-coupled P2Y12 receptor alone, i.e. independently of effects on Ca2+-signalling. From these studies we conclude that NO/cGMP inhibit Rap 1 activation in human platelets and that this effect is mediated by cGKI. Since Rap1 controls the function of integrin alpha(IIb)beta3, we propose that Rap 1 inhibition might play a central role in the anti-aggregatory actions of NO/cGMP.
Collapse
Affiliation(s)
- Oliver Danielewski
- Institute for Biochemistry II, University of Frankfurt Medical School, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany
| | | | | |
Collapse
|
12
|
Abstract
The Ras-like guanine-nucleotide-binding protein Rap1 controls integrin alpha(IIb)beta3 activity and platelet aggregation. Recently, we have found that Rap1 activation can be blocked by the nitric oxide/cyclic guanosine monophosphate (NO/cGMP) signaling pathway by type 1 cGMP-dependent protein kinase (cGKI). In search of possible targets of NO/cGMP/cGKI, we studied the expression of Rap1-specific GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) in platelets. We could detect mRNAs for a new protein most closely related to Rap1GAP and for postsynaptic density-95 discs-large and zona occludens protein 1 (PDZ)-GEF1 and CalDAG-GEFs I and III. Using 5'-rapid amplification of cDNA ends (RACE), we isolated the complete cDNA of the new GAP encoding a 715-amino acid protein, which we have termed Rap1GAP2. Rap1GAP2 is expressed in at least 3 splice variants, 2 of which are detectable in platelets. Endogenous Rap1GAP2 protein partially colocalizes with Rap1 in human platelets. In transfected cells, we show that Rap1GAP2 exhibits strong GTPase-stimulating activity toward Rap1. Rap1GAP2 is highly phosphorylated, and we have identified cGKI as a Rap1GAP2 kinase. cGKI phosphorylates Rap1GAP2 exclusively on serine 7, a residue present only in the platelet splice variants of Rap1GAP2. Phosphorylation of Rap1GAP2 by cGKI might mediate inhibitory effects of NO/cGMP on Rap1. Rap1GAP2 is the first GTPase-activating protein of Rap1 found in platelets and is likely to have an important regulatory role in platelet aggregation.
Collapse
Affiliation(s)
- Jan Schultess
- Institute for Biochemistry II, University of Frankfurt Medical School, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany
| | | | | |
Collapse
|
13
|
Smolenski A, Schultess J, Danielewski O, Garcia Arguinzonis MI, Thalheimer P, Kneitz S, Walter U, Lohmann SM. Quantitative analysis of the cardiac fibroblast transcriptome-implications for NO/cGMP signaling. Genomics 2004; 83:577-87. [PMID: 15028281 DOI: 10.1016/j.ygeno.2003.10.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2003] [Accepted: 10/06/2003] [Indexed: 11/22/2022]
Abstract
Cardiac fibroblasts regulate tissue repair and remodeling in the heart. To quantify transcript levels in these cells we performed a comprehensive gene expression study using serial analysis of gene expression (SAGE). Among 110,169 sequenced tags we could identify 30,507 unique transcripts. A comparison of SAGE data from cardiac fibroblasts with data derived from total mouse heart revealed a number of fibroblast-specific genes. Cardiac fibroblasts expressed a specific collection of collagens, matrix proteins and metalloproteinases, growth factors, and components of signaling pathways. The NO/cGMP signaling pathway was represented by the mRNAs for alpha(1) and beta(1) subunits of guanylyl cyclase, cGMP-dependent protein kinase type I (cGK I), and, interestingly, the G-kinase-anchoring protein GKAP42. The expression of cGK I was verified by RT-PCR and Western blot. To establish a functional role for cGK I in cardiac fibroblasts we studied its effect on cell proliferation. Selective activation of cGK I with a cGMP analog inhibited the proliferation of serum-stimulated cardiac fibroblasts, which express cGK I, but not higher passage fibroblasts, which contain no detectable cGK I. Currently, our data suggest that cGK I mediates the inhibitory effects of the NO/cGMP pathway on cardiac fibroblast growth. Furthermore the SAGE library of transcripts expressed in cardiac fibroblasts provides a basis for future investigations into the pathological regulatory mechanisms underlying cardiac fibrosis.
Collapse
Affiliation(s)
- Albert Smolenski
- Institute of Biochemistry II, Medical Faculty, University of Frankfurt, Theodor-Stern-Kai 7, Building 75, D-60590 Frankfurt, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Schaffeld M, Herrmann H, Schultess J, Markl J. Vimentin and desmin of a cartilaginous fish, the shark Scyliorhinus stellaris: sequence, expression patterns and in vitro assembly. Eur J Cell Biol 2001; 80:692-702. [PMID: 11824788 DOI: 10.1078/0171-9335-00206] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
In the shark Scyliorhinus stellaris we have biochemically identified and cDNA-cloned orthologs of human vimentin and desmin, SstV and SstD, as deduced from immunoblotting and sequence alignment with teleost, frog and human vimentin and desmin, respectively. This allowed us to further clarify the relationship of previously identified lower vertebrate intermediate filament proteins to mammalian vimentin and desmin. Immunofluorescence microscopy with antibodies H5 and VIM13.2 showed vimentin expression in shark eye and brain and absence in epithelia, which resembles the situation in higher vertebrates. In addition, SstV is expressed in many mesenchymal cell types which corresponds to the case in terrestrial vertebrates but strongly differs from teleosts. Surprisingly, shark interstitial cells, including fibroblasts, express neither SstV nor keratins but other as yet unidentified intermediate filament proteins as deduced from their reactivity with antibody IFA. In vitro assembly studies of recombinant SstV revealed a temperature optimum for uncompromised filament assembly of 15 degrees C. At 18 degrees C, but more pronounced at 21 degrees C and 24 degrees C, which is notably above the animal's inherent preferred environmental temperature, both, SstV and SstD assemble into thick and inflexible fibers. Thus, environmental temperature apparently is, as a general principle, a driving force for the fine tuning of protein primary structure and eventually 3D structure.
Collapse
Affiliation(s)
- M Schaffeld
- Institute of Zoology, Johannes Gutenberg University, Mainz/Germany
| | | | | | | |
Collapse
|